Literature DB >> 16686903

Experimental migraine models and their relevance in migraine therapy.

U Arulmani1, S Gupta, A Maassen VanDenBrink, D Centurión, C M Villalón, P R Saxena.   

Abstract

Although the understanding of migraine pathophysiology is incomplete, it is now well accepted that this neurovascular syndrome is mainly due to a cranial vasodilation with activation of the trigeminal system. Several experimental migraine models, based on vascular and neuronal involvement, have been developed. Obviously, the migraine models do not entail all facets of this clinically heterogeneous disorder, but their contribution at several levels (molecular, in vitro, in vivo) has been crucial in the development of novel antimigraine drugs and in the understanding of migraine pathophysiology. One important vascular in vivo model, based on an assumption that migraine headache involves cranial vasodilation, determines porcine arteriovenous anastomotic blood flow. Other models utilize electrical stimulation of the trigeminal ganglion/nerve to study neurogenic dural inflammation, while the superior sagittal sinus stimulation model takes into account the transmission of trigeminal nociceptive input in the brainstem. More recently, the introduction of integrated models, namely electrical stimulation of the trigeminal ganglion or systemic administration of capsaicin, allows studying the activation of the trigeminal system and its effect on the cranial vasculature. Studies using in vitro models have contributed enormously during the preclinical stage to characterizing the receptors in cranial blood vessels and to studying the effects of several putative antimigraine agents. The aforementioned migraine models have advantages as well as some limitations. The present review is devoted to discussing various migraine models and their relevance to antimigraine therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686903     DOI: 10.1111/j.1468-2982.2005.01082.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

1.  Treatment of bipolar disorder with comorbid migraine.

Authors:  Abigail Ortiz; Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2010-01       Impact factor: 6.186

2.  Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.

Authors:  Zdravko Lacković; Boris Filipović; Ivica Matak; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

Review 3.  Cerebral hemodynamics in the different phases of migraine and cluster headache.

Authors:  Jakob M Hansen; Christoph J Schankin
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

Review 4.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

5.  Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries.

Authors:  Saurabh Gupta; Jair Lozano-Cuenca; Carlos M Villalón; René de Vries; Ingrid M Garrelds; Cees J J Avezaat; Jorge P van Kats; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-13       Impact factor: 3.000

6.  Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine.

Authors:  Xiaomeng Dong; Yaozhi Hu; Long Jing; Jinbo Chen
Journal:  Mol Med Rep       Date:  2015-04-15       Impact factor: 2.952

7.  Electroacupuncture at Acupoints Reverses Plasma Glutamate, Lipid, and LDL/VLDL in an Acute Migraine Rat Model: A (1) H NMR-Based Metabolomic Study.

Authors:  Zishan Gao; Xuguang Liu; Shuguang Yu; Qi Zhang; Qin Chen; Qiaofeng Wu; Juan Liu; Bo Sun; Li Fang; Jia Lin; Bing-Mei Zhu; Xianzhong Yan; Fanrong Liang
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-28       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.